

MAR 22 2007

S/N 10/583706

2007 MAR 26 PM 4:50

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	MITANI, et al.	Examiner:	Unknown
Serial No.:	10/583706	Group Art Unit:	Unknown
Filed:	June 20, 2006	Docket No.:	20078.0001USWO
Title:	METHOD OF AMPLIFYING NUCLEIC ACID AND METHOD OF DETECTING MUTATED NUCLEIC ACID USING THE SAME		

CERTIFICATE UNDER 37 CFR 1.6(d): I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on March 22, 2007.

By: Peggy Kerkhove  
Name: Peggy Kerkhove

REFUND REQUEST

Mail Stop Petition  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir or Madam:

Applicants hereby respectfully request a refund under 37 C.F.R. § 1.26. On March 20, 2007 Deposit Account No. 50-3478 was charged \$400 (Fee Code 1642) for a National Stage Search Fee. Also on March 20, 2007, Deposit Account No. 50-3478 was charged \$400 (Fee Code 1614) for extra independent claims (over three). Applicants respectfully state that the National Stage Search Fee and the independent claims fees were included in the check filed with this application. Enclosed is a copy of the Form 1390, as filed on June 20, 2006, which shows the complete breakdown of the fees paid. Therefore, Applicants respectfully request that the amount of \$800 be refunded to Deposit Account No. 50-3478.

Applicants also respectfully request a refund of the \$6650 (Fee Code 1615) and \$360 (Fee Code 1616) which was charged to Deposit Account No. 50-3478 on March 20, 2007 in view of the Preliminary Amendment filed herewith.

Respectfully submitted,

HAMRE, SCHUMANN, MUELLER &  
LARSON, P.C.  
P.O. Box 2902-0902  
Minneapolis, MN 55402-0902  
(612) 455-3800

By: Douglas P. Mueller  
Reg. No. 30,300

Dated: March 22, 2007


**52835**

PATENT TRADEMARK OFFICE

DPM/pjk

MAR 22 2007

FORM PTO-1590 (REV 10-04)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				20078.1USWO
INTERNATIONAL APPLICATION NO. PCT/JP2004/019346		INTERNATIONAL FILING DATE December 24, 2004		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) Unknown
TITLE OF INVENTION METHOD OF AMPLIFYING NUCLEIC ACID AND METHOD OF DETECTING MUTATED NUCLEIC ACID USING THE SAME		PRIORITY DATE CLAIMED December 25, 2003		
APPLICANT(S) FOR DO/EO/US MITANI, et al.				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<ol style="list-style-type: none"><li>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</li><li>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</li><li>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li><li>4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</li><li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none"><li>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li><li>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</li><li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li></ol></li><li>6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li><li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))<ol style="list-style-type: none"><li>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li><li>b. <input type="checkbox"/> have been transmitted by the International Bureau.</li><li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li><li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li></ol></li><li>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li><li>9. <input checked="" type="checkbox"/> An unsigned oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li><li>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li></ol>				
Items 11. to 16. below concern document(s) or information included:				
<ol style="list-style-type: none"><li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98, Form 1449, references.</li><li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li><li>13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</li><li>14. <input type="checkbox"/> A substitute specification.</li><li>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</li><li>16. <input checked="" type="checkbox"/> Other items or information: Application Data Sheet, Communication Regarding Requested Figure, paper copy of Sequence Listing, computer readable form of the Sequence Listing, International Publication Page, Form PCT/ISA/210, Form PCT/IB/306</li></ol>				

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) Unknown		INTERNATIONAL APPLICATION NO. PCT/JP2004/019346		ATTORNEY'S DOCKET NUMBER 20078.1USWO		
<b>BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):</b>						
<input checked="" type="checkbox"/> a) Basic National fee.....		\$300.00		\$300.00		
<input type="checkbox"/> b) Examination fee.....		\$200.00		\$200.00		
<input checked="" type="checkbox"/> c) Search fee.....		\$500.00		\$500.00 *		
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$1000.00		
<input checked="" type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.						
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)		Rate		
106	-100 = 1	1		X \$250.00	\$250.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$		
CLAIMS	NUMBER FILED	NUMBER EXTRA		RATE		
Total claims	83	-20 = 63		X \$50.00	\$3150.00	
Independent claims	8	-3 = 5		X \$200.00	\$1000.00 *	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$360.00	\$	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$5400.00		
Reduction by 1/2 for filing by small entity, if applicable. Small entity status is claimed pursuant to 37 CFR 1.27				\$		
<b>SUBTOTAL =</b>				\$5400.00		
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+ \$		
<b>TOTAL NATIONAL FEE =</b>				\$5400.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+ \$		
<b>TOTAL FEES ENCLOSED =</b>				\$5400.00		
				Amount to be refunded	\$	
				charged	\$	
a. <input checked="" type="checkbox"/> Check(s) in the amount of \$5,400 to cover the above fees is enclosed.						
b. <input type="checkbox"/> Please charge the amount of \$ to cover the required filing fee for a large entity to the credit card listed on the enclosed credit card authorization form.						
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-3478.						
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.						
SEND ALL CORRESPONDENCE TO: Douglas P. Mueller Hamre, Schumann, Mueller & Larson, P.C. P.O. Box 2902-0902 Minneapolis, MN 55402						
				SIGNATURE: 		
				NAME: Douglas P. Mueller		
				REGISTRATION NUMBER: 30,300		

RECEIVED  
CENTRAL FAX CENTER

MAR 22 2007

S/N 10/583706

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	MITANI, et al.	Examiner:	Unknown
Serial No.:	10/583706	Group Art Unit:	Unknown
Filed:	June 20, 2006	Docket No.:	20078.0001USWO
Title:	METHOD OF AMPLIFYING NUCLEIC ACID AND METHOD OF DETECTING MUTATED NUCLEIC ACID USING THE SAME		

CERTIFICATE UNDER 37 CFR 1.6(d): I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on March 22, 2007.

By:   
Name: Peggy Kerkhove

PRELIMINARY AMENDMENT

Mail Stop Petition  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In connection with the above-identified application filed herewith, please enter the following preliminary amendment:

Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this paper.

Remarks begin on page 16 of this paper.

RECEIVED  
CENTRAL FAX CENTER  
MAR 22 2007

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (ORIGINAL) A primer set comprising at least two primers that allows a target nucleic acid sequence to be amplified,

wherein a first primer included in the primer set contains, in its 3' end portion, a sequence (Ac') that hybridizes to a sequence (A) located in the 3' end portion of the target nucleic acid sequence, and also contains, on the 5' side of the sequence (Ac'), a sequence (B') that hybridizes to a complementary sequence (Bc) to a sequence (B) that is present on the 5' side with respect to the sequence (A) in the target nucleic acid sequence, and

a second primer included in the primer set contains, in its 3' end portion, a sequence (Cc') that hybridizes to a sequence (C) located in the 3' end portion of a complementary sequence to the target nucleic acid sequence, and also contains, on the 5' side of the sequence (Cc'), a folded sequence (D-Dc') that contains, on the same strand, two nucleic acid sequences that hybridize to each other.

2. (ORIGINAL) The primer set according to claim 1, further comprising a third primer that hybridizes to the target nucleic acid sequence or the complementary sequence thereto,

wherein the third primer does not compete with other primers for hybridization to the target nucleic acid sequence or the complementary sequence thereto.

3. (ORIGINAL) The primer set according to claim 1, wherein in the first primer, when no intervening sequence is present between the sequence (Ac') and the sequence (B'), a ratio  $(X-Y)/X$  is in a range of -1.00 to 1.00, where  $X$  denotes the number of bases contained in the sequence (Ac') while  $Y$  indicates the number of bases contained in a region flanked by the sequence (A) and the sequence (B) in the target nucleic acid sequence, and when an intervening sequence is present between the sequence (Ac') and

the sequence (B') in the primer, a ratio  $(X-(Y-Y'))/X$  is in a range of -1.00 to 1.00, where  $X$  and  $Y$  denote the same as described above, and  $Y'$  indicates the number of bases contained in the intervening sequence.

4. (ORIGINAL) The primer set according to claim 1, wherein in the second primer, the folded sequence (D-Dc') has a length of 2 to 1000 nucleotides;

5. (ORIGINAL) The primer set according to claim 1, wherein at least one primer included in the primer set has a solid-phase support or a site that can bind to a solid-phase support.

6. (ORIGINAL) The primer set according to claim 5, wherein the solid-phase support is one selected from the group consisting of a water-insoluble organic polymer support, a water-insoluble inorganic polymer support, a synthetic polymer support, a phase transition support, a metal colloid, and a magnetic particle.

7. (ORIGINAL) The primer set according to claim 5, wherein the site that can bind to a solid-phase support is selected from the group consisting of biotin, avidin, streptoavidin, an antigen, an antibody, a ligand, a receptor, a nucleic acid, and a protein.

8. (CURRENTLY AMENDED) A method of amplifying a target nucleic acid sequence contained in a template nucleic acid, the method comprising:

- (a) preparing a template nucleic acid containing a target nucleic acid sequence;
- (b) preparing a primer set according to ~~any one of claims 1 to 7~~ claim 1; and
- (c) performing a nucleic acid amplification reaction in the presence of the template nucleic acid using the primer set.

9. (ORIGINAL) The method according to claim 8, wherein the nucleic acid amplification reaction is performed isothermally.

10. (ORIGINAL) The method according to claim 8, wherein a polymerase having strand displacement ability is used.
11. (ORIGINAL) The method according to claim 8, wherein the nucleic acid amplification reaction is performed in the presence of a melting temperature adjusting agent.
12. (ORIGINAL) The method according to claim 11, wherein the melting temperature adjusting agent is dimethyl sulfoxide, betaine, formamide, glycerol, or a mixture of two or more of them.
13. (ORIGINAL) The method according to claim 8, wherein the nucleic acid amplification reaction is performed in the presence of an enzyme stabilizing agent.
14. (ORIGINAL) The method according to claim 13, wherein the enzyme stabilizing agent is trehalose, sorbitol, mannitol, or a mixture of two or more of them.
15. (CURRENTLY AMENDED) A method of determining the presence or absence of a mutation in a nucleic acid sequence contained in a nucleic acid sample, the method comprising:
- (a) preparing a nucleic acid sample;
  - (b) preparing a primer set according to ~~any one of claims 1 to 7~~ claim 1 that is designed so that a nucleic acid sequence with or without the mutation serves as a target nucleic acid sequence, and a nucleotide residue associated with the mutation is contained in a sequence (A), a sequence (B), or a sequence (C); and
  - (c) performing a nucleic acid amplification reaction in the presence of the nucleic acid sample using the primer set.
16. (ORIGINAL) The method according to claim 15, wherein in the process (b), a primer set is prepared that is designed so that the nucleotide residue associated with the mutation is contained in the sequence (A).

17. (ORIGINAL) The method according to claim 15, wherein in the process (b), a primer set is prepared that is designed so that the nucleotide residue associated with the mutation is contained in the sequence (B).
18. (ORIGINAL) The method according to claim 15, wherein in the process (b), a primer set is prepared that is designed so that the nucleotide residue associated with the mutation is contained in the sequence (C).
19. (ORIGINAL) The method according to claim 15, wherein the nucleic acid amplification reaction is performed in the presence of a mismatch binding protein.
20. (ORIGINAL) The method according to claim 15, wherein the nucleic acid amplification reaction is performed isothermally.
21. (ORIGINAL) The method according to claim 15, wherein a polymerase having strand displacement ability is used.
22. (ORIGINAL) The method according to claim 15, wherein the nucleic acid amplification reaction is performed in the presence of a melting temperature adjusting agent.
23. (ORIGINAL) The method according to claim 22, wherein the melting temperature adjusting agent is dimethyl sulfoxide, betaine, formamide, glycerol, or a mixture of two or more of them.
24. (ORIGINAL) The method according to claim 15, wherein the nucleic acid amplification reaction is performed in the presence of an enzyme stabilizing agent.
25. (ORIGINAL) The method according to claim 24, wherein the enzyme stabilizing agent is trehalose, sorbitol, mannitol, or a mixture of two or more of them.



26. (CURRENTLY AMENDED) A method of determining the presence or absence of a deletion or insertion of a sequence in a nucleic acid sequence contained in a nucleic acid sample, the method comprising:

(a) preparing a nucleic acid sample;

(b) preparing a primer set according to ~~any one of claims 1 to 7~~ claim 1 that is designed so that a nucleic acid sequence with or without a sequence associated with a deletion or insertion serves as a target nucleic acid sequence, and a site associated with the deletion or insertion is contained in a sequence (A), a sequence (B), or a sequence (C), or is positioned between the sequence (A) and the sequence (B) or between the sequence (A) and the sequence (C); and

(c) performing a nucleic acid amplification reaction in the presence of the nucleic acid sample using the primer set.

27. (ORIGINAL) The method according to claim 26, wherein in the process (b), a primer set is prepared that is designed so that the site associated with the deletion or insertion is positioned between the sequence (A) and the sequence (B).

28. (ORIGINAL) The method according to claim 26, wherein the sequence associated with the deletion or insertion is an intronic sequence that is contained in a gene on a genome.

29. (ORIGINAL) The method according to claim 26, wherein the target nucleic acid sequence is mRNA.

30. (ORIGINAL) The method according to claim 26, wherein the nucleic acid amplification reaction is performed isothermally.

31. (ORIGINAL) The method according to claim 26, wherein a polymerase having strand displacement ability is used.

32. (ORIGINAL) The method according to claim 26, wherein the nucleic acid amplification reaction is performed in the presence of a melting temperature adjusting agent.

33. (ORIGINAL) The method according to claim 32, wherein the melting temperature adjusting agent is dimethyl sulfoxide, betaine, formamide, glycerol, or a mixture of two or more of them.

34. (ORIGINAL) The method according to claim 26, wherein the nucleic acid amplification reaction is performed in the presence of an enzyme stabilizing agent.

35. (ORIGINAL) The method according to claim 34, wherein the enzyme stabilizing agent is trehalose, sorbitol, mannitol, or a mixture of two or more of them.

36. (ORIGINAL) A method of determining the presence or absence of a mutation in a nucleic acid sequence contained in a nucleic acid sample, the method comprising:

(a) preparing a nucleic acid sample;

(b) preparing a primer set that allows a target nucleic acid sequence containing a site associated with a mutation to be amplified, the primer set being designed so that when at least one primer included in the primer set hybridizes to a nucleic acid sequence contained in the nucleic acid sample or a complementary sequence thereto, at least one mismatch occurs between the at least one primer and the nucleic acid sequence or the complementary sequence thereto, depending on the presence or absence of the mutation; and

(c) performing a nucleic acid amplification reaction in the presence of a substance having mismatch recognition ability, using the primer set in which the nucleic acid sample serves as a template.

37. (ORIGINAL) The method according to claim 36, wherein the primer set allows the target nucleic acid sequence to be amplified isothermally, and the nucleic acid amplification reaction is performed isothermally.

38. (ORIGINAL) The method according to claim 36, wherein the substance having mismatch recognition ability is a mismatch binding protein.

39. (ORIGINAL) The method according to claim 38, wherein the mismatch binding protein is MutS, MSH2, MSH6, or a mixture of two or more of them.

40. (ORIGINAL) The method according to claim 36, wherein a first primer included in the primer set contains, in its 3' end portion, a sequence (Ac') that hybridizes to a sequence (A) located in the 3' end portion of the target nucleic acid sequence, and also contains, on the 5' side of the sequence (Ac'), a sequence (B') that hybridizes to a complementary sequence (Bc) to a sequence (B) that is present on the 5' side with respect to the sequence (A) in the target nucleic acid sequence.

41. (ORIGINAL) The method according to claim 40, wherein the first primer is designed so that at least one mismatch occurs between the sequence (A) and the sequence (Ac'), depending on the presence or absence of the mutation.

42. (ORIGINAL) The method according to claim 40, wherein the first primer is designed so that at least one mismatch occurs between the sequence (Bc) and the sequence (B'), depending on the presence or absence of the mutation.

43. (ORIGINAL) The method according to claim 36, wherein a second primer included in the primer set contains, in its 3' end portion, a sequence (Cc') that hybridizes to a sequence (C) located in the 3' end portion of a complementary sequence to the target nucleic acid sequence, and also contains, on the 5' side of the sequence (Cc'), a folded sequence (D-Dc') that contains, on the same strand, two nucleic acid sequences that hybridize to each other.

44. (ORIGINAL) The method according to claim 43, wherein the second primer is designed so that at least one mismatch occurs between the sequence (C) and the sequence (Cc'), depending on the presence or absence of the mutation.

45. (ORIGINAL) The method according to claim 36, wherein the primer set further comprises a third primer that hybridizes to the target nucleic acid sequence or a complementary sequence thereto and that does not compete with other primers for hybridization to the target nucleic acid sequence or the complementary sequence thereto.

46. (ORIGINAL) The method according to claim 45, wherein the third primer is designed so that when the third primer hybridizes to the nucleic acid sequence contained in the nucleic acid sample or the complementary sequence thereto, at least one mismatch occurs between the third primer and the nucleic acid sequence or the complementary sequence thereto, depending on the presence or absence of the mutation.

47. (ORIGINAL) The method according to claim 36, wherein a polymerase having strand displacement ability is used.

48. (ORIGINAL) The method according to claim 36, wherein the nucleic acid amplification reaction is performed in the presence of a melting temperature adjusting agent.

49. (ORIGINAL) The method according to claim 48, wherein the melting temperature adjusting agent is dimethyl sulfoxide, betaine, formamide, glycerol, or a mixture of two or more of them.

50. (ORIGINAL) The method according to claim 36, wherein the nucleic acid amplification reaction is performed in the presence of an enzyme stabilizing agent.

51. (ORIGINAL) The method according to claim 50, wherein the enzyme stabilizing agent is trehalose, sorbitol, mannitol, or a mixture of two or more of them.

52. (ORIGINAL) A kit for determining the presence or absence of a mutation in a nucleic acid sequence contained in a nucleic acid sample, the kit comprising:  
(a) a substance having mismatch recognition ability; and  
(b) a primer set that allows a target nucleic acid sequence containing a site associated with a mutation to be amplified, at least one primer included in the primer set being designed so that when the at least one primer hybridizes to the nucleic acid sequence contained in the nucleic acid sample or a complementary sequence thereto, at least one mismatch occurs between the at least one primer and the nucleic acid sequence or the complementary sequence thereto, depending on the presence or absence of the mutation.

53. (ORIGINAL) The kit according to claim 52, wherein the primer set allows the target nucleic acid sequence to be amplified isothermally.

54. (ORIGINAL) The kit according to claim 52, wherein the substance having mismatch recognition ability is a mismatch binding protein.

55. (ORIGINAL) The kit according to claim 54, wherein the mismatch binding protein is MutS, MSH2, MSH6, or a mixture of two or more of them.

56. (ORIGINAL) The kit according to claim 52, wherein a first primer included in the primer set contains, in its 3' end portion, a sequence (Ac') that hybridizes to a sequence (A) located in the 3' end portion of the target nucleic acid sequence, and also contains, on the 5' side of the sequence (Ac'), a sequence (B') that hybridizes to a complementary sequence (Bc) to a sequence (B) that is present on the 5' side with respect to the sequence (A) in the target nucleic acid sequence.

57. (ORIGINAL) The kit according to claim 56, wherein the first primer is designed so that at least one mismatch occurs between the sequence (A) and the sequence (Ac'), depending on the presence or absence of the mutation.

58. (ORIGINAL) The kit according to claim 56, wherein the first primer is designed so that at least one mismatch occurs between the sequence (Bc) and the sequence (B'), depending on the presence or absence of the mutation.

59. (ORIGINAL) The kit according to claim 52, wherein a second primer included in the primer set contains, in its 3' end portion, a sequence (Cc') that hybridizes to a sequence (C) located in the 3' end portion of a complementary sequence to the target nucleic acid sequence, and also contains, on the 5' side of the sequence (Cc'), a folded sequence (D-Dc') that contains, on the same strand, two nucleic acid sequences that hybridize to each other.

60. (ORIGINAL) The kit according to claim 59, wherein the second primer is designed so that at least one mismatch occurs between the sequence (C) and the sequence (Cc'), depending on the presence or absence of the mutation.

61. (ORIGINAL) The kit according to claim 52, further comprising a third primer that hybridizes to the target nucleic acid sequence or a complementary sequence thereto, wherein the third primer does not compete with other primers for hybridization to the target nucleic acid sequence or the complementary sequence thereto.

62. (ORIGINAL) The kit according to claim 61, wherein the third primer is designed so that when the third primer hybridizes to the nucleic acid sequence contained in the nucleic acid sample or the complementary sequence thereto, at least one mismatch occurs between the third primer and the nucleic acid sequence or the complementary sequence thereto, depending on the presence or absence of the mutation.

63. (ORIGINAL) The kit according to claim 52, further comprising a polymerase having strand displacement ability.

64. (ORIGINAL) A method of determining the presence or absence of a mutation in a nucleic acid sequence contained in a nucleic acid sample, the method comprising:

- (a) preparing a nucleic acid sample;
- (b) preparing a primer set that allows a target nucleic acid sequence containing a site associated with a mutation to be amplified;
- (c) preparing a nucleic acid fragment that hybridizes to the target nucleic acid sequence and that is designed so that when the nucleic acid fragment hybridizes to a nucleic acid sequence contained in the nucleic acid sample or a complementary sequence thereto, at least one mismatch occurs between the nucleic acid fragment and the nucleic acid sequence or the complementary sequence thereto, depending on the presence or absence of the mutation; and
- (d) performing a nucleic acid amplification reaction in the presence of a substance having mismatch recognition ability and the nucleic acid fragment, using the primer set in which the nucleic acid sample serves as a template.

65. (ORIGINAL) The method according to claim 64, wherein the primer set allows the target nucleic acid sequence to be amplified isothermally, and the nucleic acid amplification reaction is performed isothermally.

66. (ORIGINAL) The method according to claim 64, wherein the substance having mismatch recognition ability is a mismatch binding protein.

67. (ORIGINAL) The method according to claim 66, wherein the mismatch binding protein is MutS, MSH2, MSH6, or a mixture of two or more of them.

68. (ORIGINAL) The method according to claim 64, wherein a first primer included in the primer set contains, in its 3' end portion, a sequence (Ac') that hybridizes to a sequence (A) located in the 3' end portion of the target nucleic acid sequence, and also contains, on the 5' side of the sequence (Ac'), a sequence (B') that hybridizes to a complementary sequence (Bc) to a sequence (B) that is present on the 5' side with respect to the sequence (A) in the target nucleic acid sequence.

69. (ORIGINAL) The method according to claim 64, wherein a second primer included in the primer set contains, in its 3' end portion, a sequence (Cc') that hybridizes to a sequence (C) located in the 3' end portion of a complementary sequence to the target nucleic acid sequence, and also contains, on the 5' side of the sequence (Cc'), a folded sequence (D-Dc') that contains, on the same strand, two nucleic acid sequences that hybridize to each other.

70. (ORIGINAL) The method according to claim 64, wherein the primer set further comprises a third primer that hybridizes to the target nucleic acid sequence or a complementary sequence thereto and that does not compete with other primers for hybridization to the target nucleic acid sequence or the complementary sequence thereto.

71. (ORIGINAL) The method according to claim 64, wherein a polymerase having strand displacement ability is used.

72. (ORIGINAL) The method according to claim 64, wherein the nucleic acid amplification reaction is performed in the presence of a melting temperature adjusting agent.

73. (ORIGINAL) The method according to claim 72, wherein the melting temperature adjusting agent is dimethyl sulfoxide, betaine, formamide, glycerol, or a mixture of two or more of them.

74. (ORIGINAL) The method according to claim 64, wherein the nucleic acid amplification reaction is performed in the presence of an enzyme stabilizing agent.

75. (ORIGINAL) The method according to claim 74, wherein the enzyme stabilizing agent is trehalose, sorbitol, mannitol, or a mixture of two or more of them.

76. (ORIGINAL) A kit for determining the presence or absence of a mutation in a nucleic acid sequence contained in a nucleic acid sample, the kit comprising:



- (a) a substance having mismatch recognition ability; and
- (b) a primer set that allows a target nucleic acid sequence containing a site associated with a mutation to be amplified; and
- (c) a nucleic acid fragment that hybridizes to the target nucleic acid sequence, the nucleic acid fragment being designed so that when the nucleic acid fragment hybridizes to the nucleic acid sequence contained in the nucleic acid sample or a complementary sequence thereto, at least one mismatch occurs between the nucleic acid fragment and the nucleic acid sequence or the complementary sequence thereto, depending on the presence or absence of the mutation.

77. (ORIGINAL) The kit according to claim 76, wherein the primer set allows the target nucleic acid sequence to be amplified isothermally.

78. (ORIGINAL) The kit according to claim 76, wherein the substance having mismatch recognition ability is a mismatch binding protein.

79. (ORIGINAL) The kit according to claim 78, wherein the mismatch binding protein is MutS, MSH2, MSH6, or a mixture of two or more of them.

80. (ORIGINAL) The kit according to claim 76, wherein a first primer included in the primer set contains, in its 3' end portion, a sequence (Ac') that hybridizes to a sequence (A) located in the 3' end portion of the target nucleic acid sequence, and also contains, on the 5' side of the sequence (Ac'), a sequence (B') that hybridizes to a complementary sequence (Bc) to a sequence (B) that is present on the 5' side with respect to the sequence (A) in the target nucleic acid sequence.

81. (ORIGINAL) The kit according to claim 76, wherein a second primer included in the primer set contains, in its 3' end portion, a sequence (Cc') that hybridizes to a sequence (C) located in the 3' end portion of a complementary sequence to the target nucleic acid sequence, and also contains, on the 5' side of the sequence (Cc'), a folded

sequence (D-Dc') that contains, on the same strand, two nucleic acid sequences that hybridize to each other.

82. (ORIGINAL) The kit according to claim 76, wherein the primer set further comprises a third primer that hybridizes to the target nucleic acid sequence or a complementary sequence thereto, and the third primer does not compete with other primers for hybridization to the target nucleic acid sequence or the complementary sequence thereto.

83. (ORIGINAL) The kit according to claim 76, further comprising a polymerase having strand displacement ability.

RECEIVED  
CENTRAL FAX CENTER  
MAR 22 2007

REMARKS

The above preliminary amendment is made to remove multiple dependencies from claims 8, 15, 26, 36, 52, 64 and 76.


Applicants respectfully request that the preliminary amendment described herein be entered into the record prior to calculation of the filing fee and prior to examination and consideration of the above-identified application.

If a telephone conference would be helpful in resolving any issues concerning this communication, please contact Applicants' primary attorney-of record, Douglas P. Mueller (Reg. No. 30,300), at (612) 455.3804.

Respectfully submitted,

HAMRE, SCHUMANN, MUELLER &  
LARSON, P.C.  
P.O. Box 2902-0902  
Minneapolis, MN 55402-0902  
(612) 455-3800

Dated: March 22, 2007

By:   
Douglas P. Mueller  
Reg. No. 30,300

DPM/pjk



RECEIVED  
CENTRAL FAX CENTER

MAR 22 2007



# HAMRE, SCHUMANN, MUELLER & LARSON, P.C.

AN INTERNATIONAL INTELLECTUAL PROPERTY LAW FIRM

FAX TRANSMISSION March 22, 2007

TO: Mail Stop: AMENDMENT  
Examiner:  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

FROM: Douglas P. Mueller

OUR REF: 20078.0001USWO

TELEPHONE: (612) 455.3800

Total pages, including cover letter: 20

PTO FAX NUMBER: 571.273.8300

If all pages are NOT received, please call us at 612.455.3800 or fax us at 612.455.3801.

Title of Document: Refund Request, copy of Form 1390 filed on June 20, 2006,  
Preliminary Amendment

Applicant: MITANI, et al.  
Serial No.: 10/583,706  
App. Filed: June 20, 2006

Group Art No.: Unknown

Adjustment Date: 05/07/2007 SAHME1

03/20/2007 SAHME1 00000002 503478 10583706

01 FC:1615 6650.00 CR -1750.00 OP

02 FC:1614 400.00 CR Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient

03 FC:1616 360.00 CR number of months to enter these papers, if appropriate.

04 FC:1642 400.00 CR

By:   
Name: Douglas P. Mueller  
Reg. No.: 30,300

Repln. Ref: 05/07/2007 SAHME1 0007534400

DAH: 503478 Name/Number: 10583706

FC: 9204 I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark  
Office on the date shown below.

05/07/2007 SAHME1 00000003 503478 10583706

Sale Ref: 00000005 DAH: 503478 10583706

01 FC:1614 400.00 DA

Signature

March 22, 2007

Date

05/07/2007 SAHME1 00000002 503478 10583706

Sale Ref: 00000004 DAH: 503478 10583706

01 FC:1642 400.00 DA

225 SOUTH SIXTH STREET - SUITE 2650 - MINNEAPOLIS - MN 55402  
TEL. 612.455.3800 - FAX 612.455.3801  
WWW.HSM.COM - MAIL@HSM.COM